First report on class 1 integrons and trimethoprim-resistance genes from dfrA group in uropathogenic E. coli (UPEC) from the aleppo area in syria

Bodour Al-Assil, Maysa Mahfoud and Abdul Rezzak Hamzeh*

1Department of Biochemistry and Microbiology; Faculty of Pharmacy; University of Aleppo; Aleppo, Syria

Keywords: urinary tract infections, antibiotic resistance, DfrA1, DfrA17,7

Horizontal gene transfer (HGT) introduces advantageous genetic elements into pathogenic bacteria using tools such as class1 integrons. This study aimed at investigating the distribution of these integrons among uropathogenic E. coli (UPEC) isolated from patients in Aleppo, Syria. It also set to uncover the frequencies of the clinically relevant DfrA1 and DfrA17,7, as well as various associations leading to reduced susceptibility. This study involved 75 Trimethoprim-resistant E. coli isolates from in- and outpatients with urinary tract infections (UTIs) from 3 major hospitals in Aleppo. Bacterial identification, resistance and extended-spectrum-β-lactamase (ESBL) production testing were performed according to Clinical Laboratory Standards Institute guidelines. Detection of integrons and DfrA genes was done using PCR and statistical significance was inferred through χ² (Fisher’s) test. Class1 integrons were detected in 54.6% of isolates while DfrA1 and DfrA17,7 were found in 16% and 70.6% of tested samples respectively. Furthermore, only DfrA17,7 were strongly associated with class1 integrons, as were reduced susceptibility to the majority of individual antibiotics, multidrug resistance and ESBL production. This study demonstrated the high prevalence of class1 integrons among UPEC strains in Aleppo, Syria, as well as their significant associations with MDR. This data give information for local healthcare provision using antibiotic chemotherapy.

Introduction

Urinary tract infections (UTIs) are among the most prevalent bacterial infections in humans. This constitutes a substantial financial and social burden on healthcare providers in developed countries such USA,1 and even more so for developing countries. Escherichia coli—the most prominent member of the family of Enterobacteriaceae—is the number one cause of UTIs.2 It is not uncommon for UTIs to be treated empirically with broad-spectrum antibiotics spurring more antibiotic resistance. The dissemination of resistance elements has been aided to a great extent by horizontal gene transfer. The latter process uses a number of biological tools, most notably of these tools are integrons.3 Not only can integrons harbor a number of resistance gene cassettes in tandem, but also provide a local promoter for their transcription. Furthermore, integrons are capable of expanding their collection of promoterless gene cassettes through the actions of specialized site-specific recombination enzymes; intI. Therefore they operate as fully equipped site-specific recombination systems which can reside on other mobile genetic elements such as transposons and plasmids to horizontally transfer resistance encoding genes between bacterial species, particularly within the Enterobacteriaceae family.4

Trimethoprim was a widely-used and cheap antibiotic for treating UTIs, it inhibits the enzyme dihydrofolate reductase, which is involved in the cellular biosynthesis and growth. To neutralize this inhibition bacterial cells make use of modifications in the gene encoding dihydrofolate reductase (dfr) resulting in Trimethoprim resistance.5 The association between integrons and bacterial resistance necessitates frequent identification and monitoring of integrons on the local level. Since improper use of antibiotics imposes higher levels of selective pressure, this type of epidemiological studies is most needed in developing countries such as Syria where antibiotics misuse is commonplace. With the total lack of data from our region, the objective of this study was to investigate the molecular epidemiology of integrons and certain resistance genes among isolates of uropathogenic E. coli in Aleppo, Syria. Additionally we set to uncover the level of association between MDR and ESBL production with the presence of integrons, thus providing the basis for better healthcare decisions in this context.
Table 1. Antibiotic susceptibility phenotypes of tested isolates

| Antibiotic                        | No. tested | Percent susceptible |
|-----------------------------------|------------|---------------------|
| Amoxicillin-Clavulanic acid (code CT0223B) | 75         | 42.66               |
| Cefepime (code CT0771B)           | 58.66      |
| Cefotaxime (code CT0412B)         | 56         |
| Cefotaxime (code CT0166B)         | 49.33      |
| Nitrofurantoin (code CT0036B)     | 96         |
| Piperacillin-Tazobactam (code CT0725B) | 62.66     |
| Aztreonam (code CT0264B)          | 61.33      |
| Amikacin (code CT0107B)           | 90.66      |
| Imipenem (code CT0455B)           | 100        |
| Cefoxitin (code CT0119B)          | 81.33      |
| Tigecycline (code CT1841B)        | 100        |
| Ceftriaxone (code CT0417B)        | 48         |
| Trimethoprim-Sulfamethoxazole (code CT0052B) | 20       |
| Ampicillin-Sulbactam (code CT0520B) | 12        |
| Tobramycin (code CT0056B)         | 50.66      |
| Ciprofloxacin (code CT0425B)      | 66.66      |
| Nalidixic acid (code CT0031B)     | 44         |
| Tetracycline (code CT0054B)       | 44         |
| Chloramphenicol (code CT0013B)    | 77.33      |

Results

Urine samples were collected from UTI patients during the study period in order to provide 104 unique isolates, which were studied to uncover antibiotic resistance phenotypes, as previously published by the current authors. Out of the total number of tested isolates 75 (72.1%) were resistant to Trimethoprim, and only these were taken for further phenotypic and molecular investigations in this study. Table 1 is an antibiogram that summarizes susceptibility patterns of Trimethoprim-resistant isolates. With Tigecycline and Imipenem eliciting zero resistance, and < 10% resistance was associated with each of Nitrofurantoin and Amikacin. The lowest rate of susceptibility was recorded with Ampicillin-Sulbactam (12%).

Class 1 integrons were detected in 41 out of 75 Trimethoprim resistant isolates, which amounts to 54.66%. Evidence of ESBL production was found in 46 isolates (61.33%), while 53 isolates (70.66%) could be classified as multidrug resistant. The highly significant association between carrying class 1 integrons and testing positive for ESBL production is shown in Table 2, which also displays a similarly significant association between multidrug resistance and class 1 integrons (p < 0.0001). 40 MDR isolates (out of 53) were found to be ESBL producers, and only six ESBL-producing E. coli isolates did not belong to the MDR category. Thus the association between the two characteristics is highly significant (p = 0.0002).

Upon investigating the presence of Trimethoprim-resistance genes dfrA7,17 and dfrA11 in the tested group we found that 53 isolates (70.66%) harbored dfrA7,17 while dfrA11 was detected in 12 isolate (16%) only. The presence of dfrA7,17 genes was tightly linked to class 1 integrons (p < 0.0001), this was not the case with dfrA11 as shown in Table 2. Only seven isolates (< 10%) harbored both genes simultaneously. A number of highly significant associations were found between decreased susceptibility to certain antibiotics and carrying the genes dfrA7,17. This was evident with Cephalosporins (Cefepime, Cefazidime, Cefotaxime and Ceftriaxone), Tobramycin, Ciprofloxacin, Nalidixic acid and Trimethoprim/Sulfamethoxazole with p values = 0.01. No such associations were found with other tested antibiotics. The presence of dfrA11 genes did not correlate significantly with decreased susceptibility to the antibiotics used in this study.

Very strong associations (p < 0.0001) were noted between resistance to Cephalosporins, Nalidixic acid, Ciprofloxacin and Trimethoprim/Sulfamethoxazole and the presence of class 1 integrons in tested isolates. In fact the same general trend was observed with the majority of commonly used antibiotics except for Chloramphenicol, Tetracycline and Ampicillin-Sulbactam (Table 3).

Discussion

Integrons can serve as a vital tool for bacterial survival against antibiotics because they offer a unique platform for assembling and expressing multiple genetic elements in the bacterial cell. Integrons are associated with in-house recombination/integration systems and equipped with a promoter for effective transcription. The structure of these genetic elements is very dynamic because it is affected by a number of factors that differ from one region to another, most importantly, antibiotics choice and misuse. Moreover, there is a severe paucity of data on integrons and related genetic elements from the Middle East in general; despite the high relevance of such information for a region where antibiotic surveillance is rarely practiced.

Four classes of integrons (1–4) have been identified so far, but the clinical significance of classes 2, 3 and 4 in the context of antibiotic resistance is dwarfed by that of class 1 integrons.7 This study reports for the first time the prevalence of class 1 integrons in Aleppo, Syria to be 54.66% among UPEC isolates from in- and outpatients.

International information regarding integron frequencies vary between different geographical locations and clinical settings, with a majority of studies focusing on outpatients. One geographically comprehensive study has been conducted in 16 western European countries and Canada,8 it detected class 1 integrons in 57.6% of tested Trimethoprim-resistant UPEC isolates from non-hospitalized patients. Despite the apparent similarity in the levels of class 1 integron frequencies, the European/Canadian figure is notably higher because it involves community-acquired infections only. Studies involving samples from hospitalized patients report higher levels of class 1 integrons, for example a Korean study9 showed in 2004 that 69% of Trimethoprim-resistant isolates harbored class 1 integrons. Both studies seem to report higher frequencies than the current study, probably due to geographic and temporal differences.
Table 2. Association between susceptibility to individual antibiotics, ESBL and MDR status and the presence of class 1 integrons in uropathogenic E. coli isolates from Aleppo, Syria

| Antibiotic resistance-related phenotype       | Number of isolates | Association with integrons (p value)* |
|-----------------------------------------------|--------------------|-------------------------------------|
|                                               | With class 1 integrons | Lacking class 1 integrons            |                                  |
| Amoxicillin-Clavulanic acid                   |                     |                                    |                                  |
| Susceptible                                   | 11                  | 21                                  | 0.0045                           |
| Non susceptible                               | 30                  | 13                                  |                                  |
| Cefepime                                      |                     |                                    |                                  |
| Non susceptible                               | 27                  | 4                                   | <0.0001                          |
| Susceptible                                   | 14                  | 30                                  |                                  |
| Ceftazidime                                   |                     |                                    |                                  |
| Susceptible                                   | 12                  | 30                                  | <0.0001                          |
| Non susceptible                               | 29                  | 4                                   |                                  |
| Cefotaxime                                    |                     |                                    |                                  |
| Susceptible                                   | 9                   | 28                                  | <0.0001                          |
| Non susceptible                               | 32                  | 6                                   |                                  |
| Nitrofurantoin                                |                     |                                    |                                  |
| Susceptible                                   | 41                  | 31                                  | 0.0091                           |
| Non susceptible                               | 0                   | 3                                   |                                  |
| Piperacillin-Tazobactam                       |                     |                                    |                                  |
| Susceptible                                   | 21                  | 26                                  | 0.318                            |
| Non susceptible                               | 20                  | 8                                   |                                  |
| Aztreonam                                     |                     |                                    |                                  |
| Susceptible                                   | 17                  | 29                                  | 0.0012                           |
| Non susceptible                               | 24                  | 5                                   |                                  |
| Amikacin                                      |                     |                                    |                                  |
| Susceptible                                   | 34                  | 34                                  | 0.014                            |
| Non susceptible                               | 7                   | 0                                   |                                  |
| Cefoxitin                                     |                     |                                    |                                  |
| Susceptible                                   | 28                  | 33                                  | 0.002                            |
| Non susceptible                               | 13                  | 1                                   |                                  |
| Ceftriaxone                                   |                     |                                    |                                  |
| Susceptible                                   | 9                   | 27                                  | <0.0001                          |
| Non susceptible                               | 32                  | 7                                   |                                  |
| Trimethoprim-Sulfamethoxazole                 |                     |                                    |                                  |
| Susceptible                                   | 1                   | 14                                  | <0.0001                          |
| Non susceptible                               | 40                  | 20                                  |                                  |
| Ampicillin-Sulbactam                          |                     |                                    |                                  |
| Susceptible                                   | 2                   | 7                                   | 0.0701                           |
| Non susceptible                               | 39                  | 27                                  |                                  |
| Tobramycin                                    |                     |                                    |                                  |
| Susceptible                                   | 13                  | 25                                  | 0.0005                           |
| Non susceptible                               | 28                  | 9                                   |                                  |
| Ciprofloxacin                                 |                     |                                    |                                  |
| Susceptible                                   | 17                  | 33                                  | <0.0001                          |
| Non susceptible                               | 24                  | 1                                   |                                  |
| Nalidixic acid                                |                     |                                    |                                  |
| Susceptible                                   | 7                   | 26                                  | <0.0001                          |
| Non susceptible                               | 34                  | 8                                   |                                  |
| Tetracycline                                  |                     |                                    |                                  |
| Susceptible                                   | 14                  | 19                                  | 0.0669                           |
| Non susceptible                               | 27                  | 15                                  |                                  |
| Chloramphenicol                               |                     |                                    |                                  |
| Susceptible                                   | 28                  | 30                                  | 0.0535                           |
| Non susceptible                               | 13                  | 4                                   |                                  |
| dfrA1                                         |                     |                                    |                                  |
| Present                                       | 5                   | 7                                   | 0.3594                           |
| Absent                                        | 36                  | 27                                  |                                  |
| dfrA2,17                                      |                     |                                    |                                  |
| Present                                       | 39                  | 14                                  | <0.0001                          |
| Absent                                        | 2                   | 20                                  |                                  |
| ESBL status                                   |                     |                                    |                                  |
| Producers                                     | 34                  | 12                                  | <0.0001                          |
| Non-producers                                 | 7                   | 22                                  |                                  |
| Multidrug resistance status                   |                     |                                    |                                  |
| MDR                                           | 41                  | 12                                  | <0.0001                          |
| Non-MDR                                       | 0                   | 22                                  |                                  |

*p values indicating significance are in bold.
in 16.6% of isolates from children with UTIs, and only less than half of these isolates carried intI1. This low prevalence may be due to limiting the study to non-hospitalized children from a sparsely urbanized locality (Jahrom, Iran). Interestingly an up-to-date study from the same country reported a much higher rate of integrons reaching 50.3% in isolates from UTI patients, which is quite comparable to the data presented in this study. However, there are many caveats in formulating solid conclusions about such country to country differences due to diverse sampling strategies which can result in highly variable frequencies.

With total lack of comparable research in Syria the closest point of reference geographically and temporally would be a relatively recent study from Lebanon. According to the latter study 30% of UPEC isolates from two hospitals in Lebanon showed evidence of class 1 integrons, and nearly all these isolates (96.7%) were resistant to Trimethoprim/Sulfamethoxazole. The prevalence of integrons in Gram negative bacilli in northwestern Turkey was investigated by Sandalli et al. with 27 integron-positive isolates out of 72 community-acquired E. coli infections (urinary and otherwise). A lower level of integron prevalence was reported by an Iranian study which detected integrons in 16.6% of isolates from children with UTIs, and only less than half of these isolates carried intI1. This low prevalence may be due to limiting the study to non-hospitalized children from a sparsely urbanized locality (Jahrom, Iran). Interestingly an up-to-date study from the same country reported a much higher rate of integrons reaching 50.3% in isolates from UTI patients, which is quite comparable to the data presented in this study. However, there are many caveats in formulating solid conclusions about such country to country differences due to diverse sampling strategies which can result in highly variable frequencies.

| Antibiotic                        | Number of isolates | Association with genes (p value) |
|-----------------------------------|--------------------|---------------------------------|
|                                   | Dfra7,17 +ve       | Dfra7,17 –ve                     | 0.077 |
| Amoxicillin-Clavulanic acid       | Susceptible        |                                 |       |
|                                   | Non susceptible    |                                 |       |
| Cefepime                          | Susceptible        |                                 | p < 0.0001 |
|                                   | Non susceptible    |                                 |       |
| Ceftazidime                       | Susceptible        |                                 | 0.0007 |
|                                   | Non susceptible    |                                 |       |
| Cefotaxime                        | Susceptible        |                                 | p < 0.0001 |
|                                   | Non susceptible    |                                 |       |
| Nitrofurantoin                    | Susceptible        |                                 | 0.2041 |
|                                   | Non susceptible    |                                 |       |
| Piperacillin-Tazobactam           | Susceptible        |                                 | 0.1189 |
|                                   | Non susceptible    |                                 |       |
| Aztreonam                         | Susceptible        |                                 | 0.0213 |
|                                   | Non susceptible    |                                 |       |
| Amikacin                          | Susceptible        |                                 | 0.0980 |
|                                   | Non susceptible    |                                 |       |
| Cefoxitin                         | Susceptible        |                                 | 0.2101 |
|                                   | Non susceptible    |                                 |       |
| Ceftriaxone                       | Susceptible        |                                 | 0.0003 |
|                                   | Non susceptible    |                                 |       |
| Trimethoprim-Sulfamethoxazole     | Susceptible        |                                 | p < 0.0001 |
|                                   | Non susceptible    |                                 |       |
| Ampicillin-Sulbactam              | Susceptible        |                                 | 0.4350 |
|                                   | Non susceptible    |                                 |       |
| Tobramycin                        | Susceptible        |                                 | 0.0003 |
|                                   | Non susceptible    |                                 |       |
| Ciprofloxacin                     | Susceptible        |                                 | 0.0004 |
|                                   | Non susceptible    |                                 |       |
| Nalidixic acid                    | Susceptible        |                                 | p < 0.0001 |
|                                   | Non susceptible    |                                 |       |
| Tetracycline                      | Susceptible        |                                 | 1.0000 |
|                                   | Non susceptible    |                                 |       |
| Chloramphenicol                   | Susceptible        |                                 | 0.0161 |
|                                   | Non susceptible    |                                 |       |

*p values indicating significance are in bold.
This study focused in particular on the most commonly encountered Trimethoprim-resistant genes in the context of medical practice; dfrA1 and dfrA7,17. The frequencies of dfrA1 and dfrA7,17 were found to be 16% and 70.66% respectively. As with integron prevalence values; different studies gave diverse accounts from different parts of the world. Our results regarding the higher prevalence of dfrA7,17 over dfrA1 echoed many findings in a number of similar studies from Lebanon,10 Denmark, The Netherlands, Korea and Australia.14 Conversely, dfrA1 appeared to be more prevalent than dfrA7,17 in Spain, Portugal, France, Belgium and Turkey.11 These differences can be attributed to a number of factors ranging from diverse sampling schemes to the genetic drift affecting horizontally transferred resistance genes.

The extremely high correlation between reduced susceptibility to individual antibiotics, MDR and ESBL production on one side and harboring integrons on the other in Aleppo corroborated well with the results from several international studies, albeit to a lesser extent. Examples include Fallah et al.13 and Farshad et al.12 from Iran, and Mathai et al.15 from southern India. In fact all integron studies reported strong association between class 1 integrons and antibiotic resistance genes such as dfrA and aadA genes.10,16,17 Thus decreased susceptibility to antimicrobials is likely to be the result of antibiotic resistance genes being carried along the same vectors (transposable elements and conjugative plasmids) as integrons. The high significance of the correlation between low susceptibility to Cephalosporins and presence of class 1 integrons in this study probably reflects the widespread misuse of this class of antibiotics in Syria. Thus detecting class 1 integrons can have a predictive value of co-resistance to antibiotics in this context. Ampicillin-Sulbactam was the only β-lactam that did not show decreased susceptibility with integrons; however this is likely to be caused by the extremely high resistance to this agent so that any changes in susceptibility would be practically undetectable. Susceptibility to Tetracycline and Chloramphenicol did not change significantly with presence of class 1 integrons, because the corresponding resistance genes may have been lost from integron-carrying plasmids due to their limited use in Syria.

In conclusion, this study presents unprecedented data about the frequency of class 1 integrons in the Aleppo governorate in Syria along with dfrA1 and dfrA7,17 that mediate Trimethoprim resistance. There is urgent need for expanding this type of investigations into the molecular epidemiology of genetic elements underlying antibiotic resistance in this part of the world. Additionally more effort is required for disseminating this information locally and internationally and formulating relevant guidelines accordingly in order to attain better levels of healthcare provision.

**Materials and Methods**

**Clinical isolates.** This study was conducted at three university hospitals in Aleppo, Syria from September to November 2011. It involved 75 UTI patients; 26 men and 49 women. Non-repetitive isolates were collected from these patients and they have been selected from a larger group on the basis of being Trimethoprim resistant. The tested cohort consisted of 43 outpatients and 32 inpatients, of the latter 8 were catheterized, and all obtained isolates were non-repetitive. Patients’ medical history was obtained to infer hospitalization status (inpatients being hospitalized for ≥ 48 h). Written informed consent was obtained from patients who provided the samples. The study protocol including the consent procedure was approved by the scientific council and the Ethical Committee at the University of Aleppo. The diagnosis of UTIs was based on microscopic findings of > 5 White Blood Cells/high power field and a colony count of 105 CFU/ml of a single pathogen using standard procedures.18

**Phenotypic study.** Urine samples were inoculated onto Nutrient and MacConkey agar with 0.001 ml calibrated loops by a semi-quantitative technique. *Escherichia coli* was identified by conventional biochemical tests using mini API® ID32E system (BioMerieux, 32400). The organisms were maintained at (~80°C) in glycerol stocks. Antimicrobial susceptibility testing was performed by standard disc diffusion method on Mueller-Hinton agar as recommended by the scientific council and the Ethical Committee at the University of Aleppo. The diagnosis of UTIs was based on microscopic findings of > 5 White Blood Cells/high power field and a colony count of 105 CFU/ml of a single pathogen using standard procedures.18

**PCR amplification.** Bacterial DNA was extracted from a single *E. coli* colony using QIAprep Spin Miniprep Kit (QIAGEN GmbH, 27104) according to manufacturer’s instructions, then stored at ~20°C as a template DNA stock. Class 1 integrons were amplified using the primers hep58 and hep59 as described.20 While the primer pairs [dfr1-f, dfr1-r] and [dfr7&17-f, dfr7&17-r] (VBC-Biotech, custom primers) were used for the detection of dfrA1 and dfrA7,17 respectively, according to Grape et al.21 Table 4 represents primer sequences in full.

**Statistical analyses.** The statistical Package for the Social Sciences (SPSS) version 19.0 was used. And the significance of associations were established using the Fisher’s exact test (p < 0.05 was considered significant).

| Target     | Primer name | Primer sequence         |
|------------|-------------|-------------------------|
| dfr1       | dfr1-forward | 5'-TGG TAG CTA TAT CGA AGA ATG GAG-3' |
|            | dfr1-reverse | 5'-TAT GTT AGA GGC GAA GTC TTG GGT A-3' |
| dfr7,17    | dfr7,17-forward | 5'-ACA TTT GAC TCT ATG GGT GTT CTT C-3' |
|            | dfr7,17-reverse | 5'-AAA ACT GTT CAA AAA CCA AAT TGA A-3' |

**Table 4. Sequences of primers used for detecting antibiotic resistance determinants in this study.**
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol 2005; 173:1281-7; PMID:15758783; http://dx.doi.org/10.1097/01.ju.0000155956.98780.82
2. Bonadio M, Meini M, Spitaleri P, Gigli C. Current microbiological and clinical aspects of urinary tract infections. Eur Urol 2001; 40:439-44, discussion 445; PMID:11713400; http://dx.doi.org/10.1159/000049813
3. Fluit AC, Schmitz FJ. Resistance integrons and super-integrons. Clin Microbiol Infect 2004; 10:272-88; PMID:15059115; http://dx.doi.org/10.1111/j.1198-743X.2004.00858.x
4. Leverstein-van Hall MA, M Blok HE, T Donders AR, Fluit AC, Schmitz FJ. Resistance integrons and super-integrons in Escherichia coli causing urinary tract infections. J Infect Dis 2003; 187:251-9; PMID:12552249; http://dx.doi.org/10.1086/345880
5. Skold O. Resistance to trimethoprim and sulfonamides. Vet Res 2001; 32:261-73; PMID:11432417; http://dx.doi.org/10.1051/vetres:2001123
6. Al-Assil B, Mahfoud M, Hamzeh AR. Resistance trends and risk factors of extended spectrum β-lactamases in Escherichia coli infections in Aleppo, Syria. Am J Infect Control 2013; pii:s0196-6553(12)01260-6; PMID:23337035
7. van Hooi AH, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJ. Acquired antibiotic resistance genes: an overview. Front Microbiol 2011; 2:209; PMID:22046172; http://dx.doi.org/10.3389/fmicb.2011.00203
8. Blalnka MT, Zalewski CA, Reuer J, Kahlmeter G, Foxman B, Mars CF. The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada. J Antimicrob Chemother 2006; 57:666-72; PMID:16464890; http://dx.doi.org/10.1093/jac/dkl020
9. Yu HS, Lee JC, Kang HY, Jeong YS, Lee EY, Choi CH, et al. Prevalence of dfr genes associated with integrons and dissemination of dfrA17 among urinary isolates of Escherichia coli in Korea. J Antimicrob Chemother 2004; 53:445-50; PMID:14963060; http://dx.doi.org/10.1093/jac/dkh097
10. El-Najjar NG, Farah MJ, Hashwa FA, Tokajian ST. Antibiotic resistance patterns and sequencing of class 1 integron from uropathogenic Escherichia coli in Lebanon. Lett Appl Microbiol 2010; 51:456-61; PMID:20840552; http://dx.doi.org/10.1111/j.1472-765X.2010.02926.x
11. Sindiali C, Buruk CK, Sancaktar M, Orgamus OB. Prevalence of integrons and a new dfrA17 variant in Gram-negative bacilli which cause community-acquired infections. Microb Immunol 2010; 54:164-9; PMID:20236427; http://dx.doi.org/10.1111/j.1348-0421.2010.00197.x
12. Farshad S, Japoni A, Hosseini M. Low distribution of integrons among multidrug resistant E. coli strains isolated from children with community-acquired urinary tract infections in Shiraz, Iran. Pol J Microbiol 2008; 57:193-8; PMID:19004259
13. Fallah F, Karimi A, Goudarzi M, Shiva F, Navidinia M, Jahosmi ME, et al. Determination of integron frequency by a polymerase chain reaction-restriction fragment length polymorphism method in multidrug-resistant Escherichia coli, which causes urinary tract infections. Microb Drug Resist 2012; 18:546-9; PMID:22816551; http://dx.doi.org/10.1089/mdr.2012.0073
14. White PA, McIver CJ, Rawlinson WD. Integrons and gene cassettes in the enterobacteriaceae. Clin Microbiol Infect 2004; 10:265-8; PMID:15751715; http://dx.doi.org/10.1111/j.1469-0691.2004.01597.x
15. Mathai E, Grape M, Kronvall G. Integrons and multidrug resistance among Escherichia coli causing community-acquired urinary tract infection in southern India. APMS 2004; 112:159-64; PMID:15153157; http://dx.doi.org/10.1111/j.1600-0463.2004.apm1120301.x
16. Grape M, Farra A, Kronvall G. Sundström L. Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. Clin Microbiol Infect 2005; 11:185-92; PMID:15751715; http://dx.doi.org/10.1111/j.1348-0421.2000.tb08906.x
17. Chang LL, Chang TM, Chang CY. Variable gene cassette patterns of class 1 integron-associated drug-resistant Escherichia coli in Taiwan. Kaohsiung J Med Sci 2007; 23:273-80; PMID:17525011; http://dx.doi.org/10.1016/S1607-551X(09)70409-7
18. Brooks GP, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg's Medical Microbiology. Twenty-Fifth Edition. New York: McGraw-Hill Medical, 2010:145-25
19. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. CLSI document M100-S20. CLSI: Wayne, PA, 2010
20. White PA, McIver CJ, Deng Y, Rawlinson WD. Characterisation of two new gene cassettes, adaA5 and dfrA17. FEMS Microbiol Lett 2000; 182:265-9; PMID:10620677; http://dx.doi.org/10.1111/j.1574-6968.2000.tb08906.x
21. Grape M, Motakefi A, Pauliuri S, Kahlmeter G. Standard and real-time multiplex PCR methods for detection of trimethoprim resistance dfr genes in large collections of bacteria. Clin Microbiol Infect 2007; 13:1112-8; PMID:17725650; http://dx.doi.org/10.1111/j.1469-0691.2007.01807.x

Acknowledgments

The authors thank the University of Aleppo, Syria for funding the work that led to this paper.